MetaCap

Immunovant (IMVT) News

NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

31.77-0.75 (-2.31%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMVT news summary

We found 9 recent headlines mentioning Immunovant (IMVT): 1 in the past week and 6 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. For price context, IMVT is down 2.31% at $31.77. The most recent story, "ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial Advances", was published by Nasdaq on Nov 19, 2026.

Headlines link to the original publishers. MetaCap does not republish third-party articles.

Summary generated from market data by MetaCap's automated system. Methodology

Latest Immunovant headlines

Stocks mentioned alongside IMVT

Compare IMVT